BioWorld Asia

Sep. 27, 2006

Merck KGaA Buying Serono, Giving CHF16.6B Valuation

Merck KGaA agreed to acquire a controlling stake in Serono SA by purchasing the Bertarelli family's shares in the company, which represent 64.5 percent of its equity and 75.5 percent of its voting rights. (BioWorld International) Read More

GPC Biotech Shares Jump On Prostate Cancer Study Results

Proteomics Approach Could Bring Rapid Dipstick For TB

Another European Agenda For Innovative Medicines

Jerini Shares Plummet On Mixed Phase III Trial News

India's Avesthagen Seeking VC Money, Eyeing 2008 IPO

BioAlliance Pharma Reports Phase I/II Doxorubicin Data

Europe Trails U.S. In Tech Transfer; Patents Lag, Too

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...